A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Inclusion Criteria: Inclusion criteria include, but are not limited to the following: 1. Between the ages of 18 and 70 years, inclusive 2. A history of molecularly confirmed PCSK9 GOFm for cohort 1 and a history of molecularly confirmed PCSK9 GOFm or ApoB LOFm 3. Plasma LDL-Cholesterol levels ≥70 mg/dL at the screening visit on a lipid-lowering therapy (LLT) regimen stable for at least 28 days Exclusion Criteria: Exclusion criteria include, but are not limited to the following: 1. Serum triglycerides \>350 mg/dL at the screening visit 2. Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus 3. Pregnant or breast-feeding women. 4. Sexually active man or woman of childbearing potential who is unwilling to practice adequate contraception during the study